PK150

2165324-62-7

394.68

DMSO : 250 mg/mL (633.42 mM; Need ultrasonic)

Anti-infection

PK150, an analogue of Sorafenib, shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 inhibits Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Vancomycin intermediate S. aureus (VISA) with MICs of 0.3, 0.3-1, 0.3 uM, respectively^[1]. IC50 & Target: MIC: 0.3 uM (MSSA), 0.3-1 uM (MRSA), 0.3 uM (VISA)^[1] In Vivo: The in vivo efficacy of PK150 against methicillin-sensitive S. aureus (MSSA) (strain SH1000) is demonstrated in a murine bloodstream infection model. PK150 (20?mg/kg; p.o.) significantly reduces bacterial loads in the liver and heart^[1].
PK150 (10 and 20mg/kg orally; or 10mg/kg intravenously) shows no obvious signs of toxicity in mice. Higher i.v. dosing of 20mg/kg results in severe toxic effects and is thus avoided for subsequent therapeutic models^[1].